Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Active Not Recruiting
NCT04959448N/AUpdated Jul 13, 2026
Sponsor: Regeneron Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyposis
United States, Canada, Germany, Italy, Japan +1 more
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisCompleted
NCT05018806Phase 2Updated Jul 13, 2026
Sponsor: Sanofi
Atopic Dermatitis
United States, Canada, Chile, Czechia, Germany +2 more
Actual Use Trial of Tadalafil 5 mgCompleted
NCT06805513Phase 3Updated Jul 13, 2026
Sponsor: Sanofi
Erectile Dysfunction
United States
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionActive Not Recruiting
NCT02843035Phase 2Updated Jul 10, 2026
Sponsor: Genzyme, a Sanofi Company
Gaucher Disease Type 1 · Gaucher Disease Type 3
United States, Germany, Japan, United Kingdom
Validation of Chlamydia Diagnostic Codes in TriNetX US EHR DataRecruiting
NCT07094373N/AUpdated Jul 10, 2026
Sponsor: Sanofi
Chlamydial Infections
United States
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisActive Not Recruiting
NCT06407934Phase 3Updated Jul 10, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Bulgaria +22 more
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusCompleted
NCT06716424Phase 4Updated Jul 10, 2026
Sponsor: Sanofi
Type 2 Diabetes
India
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII TherapiesNot Yet Recruiting
NCT07692217N/AUpdated Jul 9, 2026
Sponsor: University of Texas Southwestern Medical Center
Hemophilia A · Factor VIII (FVIII)
United States
Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical PracticeCompleted
NCT07615166N/AUpdated Jul 9, 2026
Sponsor: Sanofi
Atherosclerotic Cardiovascular Disease
United States
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcneRecruiting
NCT07013747Phase 1, Phase 2Updated Jul 9, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Acne
United States
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid TumorsRecruiting
NCT06651593Phase 2Updated Jul 9, 2026
Sponsor: M.D. Anderson Cancer Center
Solid Tumors
United States
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseRecruiting
NCT06984627Phase 2Updated Jul 7, 2026
Sponsor: Sanofi
Graves' Disease
Canada, Germany, Italy, Spain, United Kingdom
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsRecruiting
NCT07307235Phase 4Updated Jul 7, 2026
Sponsor: Shanghai Zhongshan Hospital
Type 2 Diabetes
China
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Terminated
NCT05086315Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Sanofi
Acute Lymphocytic Leukaemia · Acute Myeloid Leukaemia Refractory · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasia
United States, Australia, China, France, Netherlands
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)Recruiting
NCT05263206Phase 3Updated Jul 6, 2026
Sponsor: Sanofi
Pruritus
United States, Argentina, Canada, China, France +8 more
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)Completed
NCT03849716N/AUpdated Jul 6, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +4 more
LATE-ONSET POMPE DISEASE AND CEREBROVASCULAR MANIFESTATIONSCompleted
NCT07685314N/AUpdated Jul 6, 2026
Sponsor: Hospitales Universitarios Virgen del Rocío
Late-Onset Pompe Disease
Spain
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyEnrolling By Invitation
NCT06914908Phase 2Updated Jul 2, 2026
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps
United States, Argentina, Belgium, Bulgaria, Poland +1 more
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryNot Yet Recruiting
NCT07612878N/AUpdated Jul 2, 2026
Sponsor: Sanofi
COPD (Chronic Obstructive Pulmonary Disease)
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaActive Not Recruiting
NCT04850599Phase 2Updated Jul 2, 2026
Sponsor: OHSU Knight Cancer Institute
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
United States
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)Active Not Recruiting
NCT06687980Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Lichen Simplex Chronicus
United States, Argentina, Belgium, Canada, Chile +12 more
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on DialysisTerminated
NCT02859896Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Secondary Hyperparathyroidism-Chronic Kidney Disease
United States, Chile
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsEnrolling By Invitation
NCT05492578Phase 2, Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Bulgaria +24 more
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorRecruiting
NCT06241118Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Dermatitis Atopic
United States, Argentina, Australia, Brazil, Canada +18 more
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)Active Not Recruiting
NCT06687967Phase 3Updated Jul 2, 2026
Sponsor: Sanofi
Lichen Simplex Chronicus
United States, Argentina, Canada, Chile, China +12 more

Previous page Next page